Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- WFH guidelines for the management of hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition.Haemophilia. 2020; 26: 1-158
- Clotting defect in hemophilia: deficiency in plasma factor required for platelet utilization.Proc Soc Exp Biol Med. 1947; 66: 117-120
- Christmas disease: a condition previous mistake for haemophilia.Br Med J. 1952; 2: 137801382
- Clinical use of human prothrombin complexes.N Engl J Med. 1965; 273: 667-674
- The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States.Am J Hematol. 2020; 95: 960-965
- Biology of inherited coagulopathies: factor IX.Hematol Oncol Clin North Am. 1992; 6: 999-1009
- Identification of the endothelial cell binding site for factor IX.Proc Natl Acad Sci U S A. 1996; 93: 11068-11073
- Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo.Blood. 2002; 100: 153-158
- Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.Blood. 2016; 128: 286-292
- Extravascular FIX and coagulation.Thromb J. 2016; 14: 35
- Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.Thromb Haemost. 2002; 87 (14): 431-435
- Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.J Thromb Haemost. 2009; 7: 1843-1851
Matino D, Iorio A, Stafford D, et al. Enhanced FIX collagen IV binding shows improved hemostatic effects in a hemophilia B mouse model. Top abstract presentation, ISTH SSC Meeting. Dublin, July 18, 2018.
- Establishing the prevalence and prevalence at birth of hemophilia in males: a metaanalytic approach using national registries.Ann Intern Med. 2019; 171: 540-546
- Prevalence of sporadic and familial haemophilia.. 2007; 13: 90
- Genetic causes of haemophilia in women and girls.Haemophilia. 2020; 27: e164-e179
- Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.Haematologica. 2015; 100: e84-e86
- Haemophilia care in central Scotland 1980-94. I. Demographic characteristics, hospital admissions and causes of death.Haemophilia. 2000; 6: 494-503
- Validation of a composite score for clinical severity of hemophilia.J Thromb Haemost. 2008; 6: 1113-1121
- Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.J Thromb Haemost. 2010; 8: 737-743
- Hemophilia A and B: molecular and clinical similarities and differences.Haematologica. 2019; 104: 1702-1709
- Leyden arising de novo by point mutation in the putative factor IX promoter region.Br J Haematol. 1991; 77: 191-194
- National hemophilia foundation.(Available at:) (Accessed August 31, 2021)
- Hemophilia therapy: the future has begun.Haematologica. 2020; 105: 545-553
- Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.Thromb Haemost. 2017; 117: 1023-1030
- Inhibitor development in haemophilia B: an orphan disease in need of attention.Br J Haematol. 2007; 138: 305-315
- Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study.Haematologica. 2020; 106: 123-129
- Gene therapy to cure haemophilia: is robust scientific inquiry the missing factor?.Haemophilia. 2020; 26: 931-933
- ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor.Hamostaseologie. 2009; 29: 155-157
- rFIXFc for immune tolerance induction in a severe hemophilia B patient with an inhibitor and prior history of ITI related nephrotic syndrome.Haemophilia. 2018; 24: e294-e296
- Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.N Engl J Med. 2011; 365: 2357-2365
- Hemophilia B gene therapy with a high-specific-activity factor IX variant.N Engl J Med. 2017; 377: 2215-2227
Article info
Publication history
Published online: October 01, 2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
